Brief: Infinity Receives Fast Track Designation For Eganelisib In Combination With A Checkpoint Inhibitor And Chemotherapy For First-Line Treatment Of Advanced Tnbc
29/09/2020 12:43
Sept 29 (Reuters) - Infinity Pharmaceuticals Inc INFI.O :
* INFINITY RECEIVES FAST TRACK DESIGNATION FOR EGANELISIB IN
COMBINATION WITH A CHECKPOINT INHIBITOR AND CHEMOTHERAPY FOR
FIRST-LINE TREATMENT OF ADVANCED TNBC
* INFINITY PHARMACEUTICALS INC - CURRENTLY ENROLLING
PATIENTS IN
MARIO-3
Source text for Eikon: ID:nBw2PkjnRa
Further company coverage: INFI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX